Pfizer & Interneuron - 500 Beiträge pro Seite
eröffnet am 17.12.01 19:30:07 von
neuester Beitrag 18.12.01 15:41:10 von
neuester Beitrag 18.12.01 15:41:10 von
Beiträge: 5
ID: 523.180
ID: 523.180
Aufrufe heute: 0
Gesamt: 240
Gesamt: 240
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 55 Minuten | 5553 | |
| heute 11:09 | 3425 | |
| vor 45 Minuten | 2116 | |
| vor 35 Minuten | 2012 | |
| heute 09:10 | 1722 | |
| vor 29 Minuten | 1623 | |
| vor 48 Minuten | 1418 | |
| vor 1 Stunde | 1312 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.947,39 | -0,78 | 220 | |||
| 2. | 3. | 150,76 | -0,53 | 104 | |||
| 3. | 2. | 9,5250 | -1,24 | 93 | |||
| 4. | 4. | 0,1875 | -3,35 | 77 | |||
| 5. | 34. | 0,5700 | -59,29 | 47 | |||
| 6. | 13. | 394,75 | -14,47 | 43 | |||
| 7. | 6. | 0,0211 | -32,59 | 41 | |||
| 8. | 5. | 6,8260 | +1,22 | 40 |
Feedback
For immediate release
December 12, 2001
PFIZER INVITES PUBLIC TO LISTEN TO WEBCAST OF DECEMBER 18 MEETING WITH ANALYSTS
NEW YORK, December 12, 2001 -- Pfizer Inc invites investors and the general public to listen to a webcast at www.pfizer.com of a meeting with investment analysts being held on Tuesday, December 18 from 9:00 a.m. to approximately 12:30 p.m. Eastern Standard Time. Dr. Henry A. McKinnell, Pfizer chairman and chief executive officer, will host the meeting at which senior officers of the company will update analysts on Pfizer`s performance and prospects.
Visitors to www.pfizer.com will be able to listen to an archived copy of the webcast of the meeting through 9:00 a.m. (EST), Friday, December 28.
Pagoclone, "ein Mittel gegen Angstzustände" ist für Interneuron eines der wichtigsten Medikamente. Pfizer wird beim Analystenmeeting das Medikament vorstellen!
Wir können uns auf morgen freuen!
December 12, 2001
PFIZER INVITES PUBLIC TO LISTEN TO WEBCAST OF DECEMBER 18 MEETING WITH ANALYSTS
NEW YORK, December 12, 2001 -- Pfizer Inc invites investors and the general public to listen to a webcast at www.pfizer.com of a meeting with investment analysts being held on Tuesday, December 18 from 9:00 a.m. to approximately 12:30 p.m. Eastern Standard Time. Dr. Henry A. McKinnell, Pfizer chairman and chief executive officer, will host the meeting at which senior officers of the company will update analysts on Pfizer`s performance and prospects.
Visitors to www.pfizer.com will be able to listen to an archived copy of the webcast of the meeting through 9:00 a.m. (EST), Friday, December 28.
Pagoclone, "ein Mittel gegen Angstzustände" ist für Interneuron eines der wichtigsten Medikamente. Pfizer wird beim Analystenmeeting das Medikament vorstellen!
Wir können uns auf morgen freuen!
übrigens an der Nasdaq heute schon im "Vorfeld" knapp 6% im Plus!
Hier vielleicht alles etwas genauer über Pfizer und die Tatsache, daß heute Pfizer die Zusammenarbeit mit Interneuron und dem Medikament Pagoclone detaillierter erzählt.
Pfizer Keeps Its Outlook on the Positive Side
By Adam Feuerstein
Staff Reporter
12/17/2001 06:31 PM EST
Pfizer (PFE:NYSE - news - commentary - research - analysis) said Monday that it expects to earn at least $1.30 a share in 2001, in line with its previous forecast, though a penny shy of Wall Street expectations.
The drug giant offered the financial guidance one day ahead of a meeting with analysts in New York City.
Previously, Pfizer had forecast 2001 earnings in a range of $1.27 to $1.30 a share. Hitting the upper figure would push Pfizer`s earnings growth to 27%, tops among major pharmaceutical companies.
For 2002, Pfizer says it expects to earn $1.56 to $1.60 a share, representing 20% earnings growth. Wall Street is looking for 2002 earnings of $1.59 a share.
Shares of Pfizer closed Monday up 89 cents, or 2.26%, to $40.33.
Pfizer`s outlook contrasts sharply with that of rivals Merck (MRK:NYSE - news - commentary - research - analysis) and Bristol-Myers Squibb (BMY:NYSE - news - commentary - research - analysis), which both warned last week of flat to negative earnings growth for 2002 as drug patent expirations take their toll on sales.
But Pfizer is not without its challenges. Goldman Sachs analyst James Kelly sees earnings growth slowing to industry-average levels of 12% to 14% over 2003-05. Pfizer`s pipeline is promising, he adds, but product approvals and launches likely won`t happen until 2003 and beyond. Kelly rates Pfizer market perform, and his firm hasn`t done recent underwriting for the company.
Pfizer will provide details about its late-stage pipeline at Tuesday`s analyst meeting, which could affect shares of Inhale Therapeutics (INHL:Nasdaq - news - commentary - research - analysis) and Interneuron (IPIC:Nasdaq - news - commentary - research - analysis).
Inhale has a pact with Pfizer to develop Exubera, an inhaled insulin drug. In July, Pfizer announced that plans to file for approval of the drug with the Food and Drug Administration by the end of the year were delayed. At the time, Pfizer officials didn`t say much more but hinted that additional tests might be required. Investors and analysts will be looking for more details tomorrow, including a possible FDA filing date.
Pfizer is also conducting late-stage tests on an antianxiety drug called pagaclone, which it licensed from tiny biotech Interneuron. Pfizer is testing pagaclone as a new type of drug to treat patients suffering from panic attacks and general anxiety disorders. The drug could be big because it seems to lack some of the negative side effects of existing drugs such as Valium and Xanax. Pagaclone could reach the FDA in 2003 if all goes well, and that`s what Interneuron shareholders will be listening for tomorrow.
Pfizer Keeps Its Outlook on the Positive Side
By Adam Feuerstein
Staff Reporter
12/17/2001 06:31 PM EST
Pfizer (PFE:NYSE - news - commentary - research - analysis) said Monday that it expects to earn at least $1.30 a share in 2001, in line with its previous forecast, though a penny shy of Wall Street expectations.
The drug giant offered the financial guidance one day ahead of a meeting with analysts in New York City.
Previously, Pfizer had forecast 2001 earnings in a range of $1.27 to $1.30 a share. Hitting the upper figure would push Pfizer`s earnings growth to 27%, tops among major pharmaceutical companies.
For 2002, Pfizer says it expects to earn $1.56 to $1.60 a share, representing 20% earnings growth. Wall Street is looking for 2002 earnings of $1.59 a share.
Shares of Pfizer closed Monday up 89 cents, or 2.26%, to $40.33.
Pfizer`s outlook contrasts sharply with that of rivals Merck (MRK:NYSE - news - commentary - research - analysis) and Bristol-Myers Squibb (BMY:NYSE - news - commentary - research - analysis), which both warned last week of flat to negative earnings growth for 2002 as drug patent expirations take their toll on sales.
But Pfizer is not without its challenges. Goldman Sachs analyst James Kelly sees earnings growth slowing to industry-average levels of 12% to 14% over 2003-05. Pfizer`s pipeline is promising, he adds, but product approvals and launches likely won`t happen until 2003 and beyond. Kelly rates Pfizer market perform, and his firm hasn`t done recent underwriting for the company.
Pfizer will provide details about its late-stage pipeline at Tuesday`s analyst meeting, which could affect shares of Inhale Therapeutics (INHL:Nasdaq - news - commentary - research - analysis) and Interneuron (IPIC:Nasdaq - news - commentary - research - analysis).
Inhale has a pact with Pfizer to develop Exubera, an inhaled insulin drug. In July, Pfizer announced that plans to file for approval of the drug with the Food and Drug Administration by the end of the year were delayed. At the time, Pfizer officials didn`t say much more but hinted that additional tests might be required. Investors and analysts will be looking for more details tomorrow, including a possible FDA filing date.
Pfizer is also conducting late-stage tests on an antianxiety drug called pagaclone, which it licensed from tiny biotech Interneuron. Pfizer is testing pagaclone as a new type of drug to treat patients suffering from panic attacks and general anxiety disorders. The drug could be big because it seems to lack some of the negative side effects of existing drugs such as Valium and Xanax. Pagaclone could reach the FDA in 2003 if all goes well, and that`s what Interneuron shareholders will be listening for tomorrow.
test
Interneuron durch positive Nachrichten über Pagoclone auf dem Weg Richtung 9$!
IPIC 9:37 AM 8.91 +0.258 +2.98% N/A N/A 8.82 9.00
IPIC 9:37 AM 8.91 +0.258 +2.98% N/A N/A 8.82 9.00
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 220 | ||
| 104 | ||
| 93 | ||
| 77 | ||
| 47 | ||
| 43 | ||
| 41 | ||
| 40 | ||
| 31 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 29 | ||
| 28 | ||
| 27 | ||
| 25 | ||
| 24 | ||
| 24 | ||
| 24 | ||
| 22 | ||
| 21 | ||
| 19 |
